Cartesian Therapeutics (Cartesian Therapeutics (RNAC)) is having a good Tuesday. The stock climbed nearly 18% after the company announced a strategic licensing agreement with WestGene Biopharma. The deal gives Cartesian access to an in vivo chimeric antigen receptor T-cell (CAR-T) platform, which it plans to use to develop treatments for autoimmune diseases.

If you're not familiar with in vivo CAR-T, here's the quick version: Instead of taking a patient's cells out of the body, engineering them, and putting them back (the traditional ex vivo approach), in vivo CAR-T delivers the genetic instructions directly into the body. It's like the difference between sending a package to a factory for customization versus having a handyman come to your house. It's faster, cheaper, and potentially more scalable.

Cartesian is a clinical-stage biopharma company that has been pivoting hard toward autoimmune diseases. This partnership fits right into that strategy. WestGene gets an upfront payment and is eligible for milestone payments down the road. The first target? Myasthenia gravis, a chronic autoimmune disease that causes muscle weakness. A clinical trial is slated to start in the second half of 2026, with data expected in the first half of 2027.

This isn't Cartesian's first rodeo in autoimmune disease. The company previously paused studies in lupus and multiple myeloma as it shifted focus. Now, with this new platform, it's doubling down.

The Technical Picture: Not All Sunshine

Despite the double-digit pop, the stock's technicals tell a more cautious story. At $6.90, Cartesian shares are still about 7.3% below their 20-day simple moving average of $7.01. That's a short-term bearish signal. The moving average convergence divergence (MACD) is also below its signal line, suggesting momentum is fading. In other words, the stock needs to reclaim that moving average to convince traders the uptrend has legs.

Key levels to watch: resistance at $7.50, where the stock has stalled before, and support at $6.00, where buyers have previously stepped in. If the stock can break above $7.50, it could signal a shift in sentiment. If it falls below $6.00, the bears might take control.

What the Analysts Say

Wall Street is still bullish on Cartesian, even if recent price targets have come down. The consensus rating is Buy, with an average price target of $29.75 — that's more than four times the current price. Here are the recent analyst moves:

• Wedbush: Outperform, target maintained at $38.00 (May 27)
• Needham: Buy, target lowered to $40.00 (May 26)
• HC Wainwright & Co.: Buy, target lowered to $25.00 (May 12)

Notice the pattern: all three analysts still like the stock, but they've trimmed their price targets. That could reflect the broader market's skepticism about biotech or specific concerns about Cartesian's pipeline. Still, a $29.75 average target suggests significant upside if the company executes.

MarketDash Edge Scorecard: Weak Momentum

MarketDash's edge scorecard gives Cartesian a momentum score of 5.14 out of 100, which is considered weak. That aligns with the technical picture: the stock has been struggling to gain traction despite the positive news. The scorecard compares the stock's momentum to the broader market, and right now, it's not looking great.

The verdict? Cartesian has a compelling story — a new platform, a clear target, and analyst support — but the market isn't fully buying it yet. Investors will need to watch the upcoming clinical trial data closely. If the in vivo CAR-T approach shows promise in myasthenia gravis, the stock could have room to run. If not, the weak momentum might persist.

For now, the stock is up on the news, but the real test will come when the trial data hits in 2027.